Capricor Therapeutics, Inc.
CAPRDrugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Aug 10, 2026
5wMarket Overview
Stock performance and key metrics
2 upcoming, 1 past
How CAPR's past catalysts played out
CAP-1002
Cardiosphere-Derived Cells
Duchenne Muscular Dystrophy
Deramiocel (CAP-1002)
Duchenne Muscular Dystrophy
CAP-2003
COVID-19 Cardiac
Cenderitide
Heart Failure
Allogeneic Cardiosphere-Derived Cells (CAP-1002)
Duchenne Muscular Dystrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CAP-1002 Cardiosphere-Derived Cells | Phase 3 | Duchenne Muscular Dystrophy | OrphanFast Track | - |
Deramiocel (CAP-1002) | Phase 3 | Duchenne Muscular Dystrophy | - | - |
CAP-2003 | Phase 2 | COVID-19 Cardiac | - | - |
Cenderitide | Phase 2 | Heart Failure | - | - |
Allogeneic Cardiosphere-Derived Cells (CAP-1002) | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Capricor Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Capricor Therapeutics, Inc.'s (CAPR) pipeline across Phase 3, Phase 2. Its lead program is CAP-1002 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Capricor Therapeutics, Inc.'s next FDA catalyst?→
Capricor Therapeutics, Inc.'s (CAPR) next tracked catalyst is a Earnings expected August 10, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CAPR biotech catalysts?→
Add CAPR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Capricor Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.